In December Walgreen’s announced a 40% stake in Sinopharm Holding Guoda Drugstores in China, expanding the company’s global reach. And the pharma retailer is getting into the data game, having spent over $500 million to-date on updating pharmacy management and data collection system and turning its 88.6 million user “Balance Rewards” program into a customer insight tool. Despite these expansion efforts and stronger than expected Q2 earnings, shareholders have watched the pharma retailer’s share price drop 22% since January, largely due to Amazon’s plan to sell prescription drugs to doctors and hospitals.
Looking for leads, investment insights, or competitive intelligence?
News about Walgreens Boots Alliance
Investors fear weakness, debt in the retail sector.
The partnership will also bring Kroger's private-label brands to Walgreens shelves.
The pharmacy giant failed to disclose the risks involved in its merger with Boots Alliance, the SEC claimed.
Kaleo's allergy shot Auvi-Q will reportedly be free for those with commercial insurance.